Company Overview
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +251.51% |
| 6 Months: | +118.84% |
| 3 Months: | +94.79% |
| 1 Month: | +82.21% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)88.55 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- RSI at 89 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | YARW Yarrow Bioscience, Inc. | 35.02 | - | - | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 994.00K | 2.86M |
| Operating Income | -994.00K | -2.86M |
| EBITDA | -994.00K | -2.86M |
| Interest Expense | - | - |
| Pretax Income | -70.99M | -2.75M |
| Tax Provision | - | - |
| Net Income | -70.99M | -2.75M |
| Diluted EPS | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Total Assets | 100.41M |
| Current Assets | 100.00M |
| Cash & Equivalents | 99.99M |
| Inventory | - |
| Receivables | 0 |
| Total Liabilities | 71.55M |
| Current Liabilities | 71.55M |
| Long Term Debt | - |
| Total Debt | - |
| Total Equity | 28.86M |
| Shares Outstanding | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 0.12% | 40.00K | $1.40M |
| 2 | Lynx1 Capital Management Lp | 0.10% | 32.57K | $1.14M |
| 3 | Shay Capital LLC | 0.10% | 32.20K | $1.13M |
| 4 | Anson Funds Management LP | 0.07% | 24.86K | $870.67K |
| 5 | Adar1 Capital Management, LLC | 0.06% | 21.28K | $745.15K |
| 6 | T3 Companies, LLC | 0.06% | 18.90K | $661.88K |
| 7 | Braidwell LP | 0.05% | 18.32K | $641.64K |
| 8 | Citadel Advisors Llc | 0.03% | 10.29K | $360.32K |
| 9 | Kvp Capital Advisors, LP | 0.03% | 10.01K | $350.58K |
| 10 | Two Sigma Investments, LP | 0.03% | 8.53K | $298.65K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for YARW
YARW — Frequently Asked Questions
What is the current share price of Yarrow Bioscience, Inc. (YARW)?
As of 2026-08-02 19:16 PDT, Yarrow Bioscience, Inc. (YARW) trades at $35.02 on NasdaqCM. Its 52-week range is $8.10 to $35.02.
Is YARW a good stock to buy?
This page provides a data-driven analysis of Yarrow Bioscience, Inc. (YARW), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.